Reducing the dose of gonadotrophin-releasing hormone agonist on starting ovarian stimulation: effect on ovarian response and in-vitro fertilization outcome

By Elgendy M   Afnan M  

Human Reproduction, Vol. 13, Iss. 9, 1998-09 ,pp. : 2382-2385

Oxford University Press

Access to resources Recommend Favorite

Effectiveness of a low gonadotrophin-releasing hormone antagonist dose in preventing premature luteinizing hormone rise during controlled ovarian stimulation

By Tiboni Gian Mario   Palumbo Paola   Leonzio Emiliana   Gabriele Elisabetta   Verna Ilde   Giampietro Franca  

Gynecological Endocrinology, Vol. 27, Iss. 11, 2011-11 ,pp. : 885-889

Informa Healthcare

Access to resources Recommend Favorite

Clinical and hormonal effects of the combination gonadotrophin-releasing hormone agonist plus oral contraceptive pills containing ethinyl-oestradiol (EE) and cyproterone acetate (CPA) versus the EE-CPA pill alone on polycystic ovarian disease-related hyperandrogenisms.

By Acién P   Mauri M   Gutierrez M  

Human Reproduction, Vol. 12, Iss. 3, 1997-03 ,pp. : 423-429

Oxford University Press

Access to resources Recommend Favorite

Endocrinology. Follicular and luteal phase characteristics following early cessation of gonadotrophin-releasing hormone agonist during ovarian stimulation for in-vitro fertilization

By Beckers N.G.M.  

Human Reproduction, Vol. 15, Iss. 1, 2000-01 ,pp. : 43-49

Oxford University Press

Access to resources Recommend Favorite

Ovarian hyperstimulation following the sole administration of agonistic analogues of gonadotrophin releasing hormone

By Weissman A  

Human Reproduction, Vol. 13, Iss. 12, 1998-12 ,pp. : 3421-3424

Oxford University Press

Access to resources Recommend Favorite